“This FDA approval indicates global ... a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...

US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Otulfi is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active ...

Dong-A ST's biosimilar product Imuldosa has been approved by the U.S. Food and Drug Administration (FDA), the Korean ...

Accord BioPharma receives US FDA approval for Imuldosa, a biosimilar to Stelara to treat chronic inflammatory conditions: Our Bureau, Mumbai Monday, October 14, 2024, 16:45 Hrs [I ...

FDA approves the biologics license application (BLA) that Dong-A submitted in 2023 for Imuldosa, a biosimilar referencing ...

“The heroes here tonight are not make-believe heroes from Marvel Comics, but real-life heroes who have made an impact on ...